HDCN Abstract:  ASN Annual Meeting 2020 -- Digital Meeting  

Uffing A, Cravedi P, Riella LV

Recurrence of IgA Nephropathy After Kidney Transplantation: TANGO Multicenter Study

ASN Annual Meeting 2020 -- Digital Meeting
J Am Soc Nephrol (Oct) 31:58A 2020


In patients who received a kidney transplantation for end-stage renal disease (ESRD) due to IgA nephropathy, IgA deposits can recur in the transplanted kidney. The incidence, impact and predictors of these recurrent deposits is unclear.


As part of The Post- Transplant Glomerular Disease (TANGO) project, we performed a multicenter, international, retrospective study to determine the incidence, predictors and treatment response of recurrent IgA deposits after kidney transplantation. Patients with biopsy-proven IgA nephropathy, transplanted in the period 2005- 2015 were selected in 16 TANGO centers in Europe, the United States and Brazil.


In a total of 504 patients, recurrent IgA deposits were identified by kidney biopsy in 82 patients (16%; 95%CI: 13-19), with a median time to recurrence of 3.4 years (IQR 1.4-5.7 years). Kaplan- Meier analysis showed similar graft survival between patients with and without recurrence in the first years after kidney transplant, though after 8 years, graft failure rates were higher in patients with recurrence (10-year death-censored graft survival 76% and 89%, respectively). Multivariable Cox- regression revealed a higher risk for IgA recurrence in patients with a pre- emptive kidney transplant (HR 2.56, 95%CI: 1.59-4.17), patients with DSA at time of transplant (HR 2.74, 95%CI: 1.22-6.14) and patients with a shorter time from diagnosis to ESRD (HR 0.84 per month, 95%CI: 0.74-0.96). The presence of systemic auto-immune diseases associated with IgA nephropathy did not affect recurrence rates, nor did early steroid withdrawal. In multivariate analysis of post-transplant complications, de novo DSA was associated with recurrence of IgA deposits (HR 1.91, 95%CI: 1.04-3.51).


In our international cohort, IgA deposits recurred in 16% of patients and was associated with worse graft outcomes after 8 years of transplant compared to patients without recurrence. A pre-emptive transplant, shorter time from native diagnosis to ESRD, DSA at time of transplant and de novo DSA after kidney transplantation were associated with recurrence of IgA deposits

c Copyright 2020 -2021 American Society of Nephrology. Reproduced with permission.
All ASN abstracts from the 2020 Annual Meeting are available at this link and also are archived in .pdf form at ASN-Online.org

Disclaimer: Abstracts often have errors, both typographical and otherwise. This posting is an electronic translation of submitted abstracts which has not been verified against the original submitted abstract nor with the authors for accuracy. As a result, there may be errors, especially with regard to drug doses, but not limited to these. Abstracts undergo only limited review, and data often are changed as a result of the peer review process, so their reliability is less than manuscripts published in peer-reviewed journals. In using these summaries, you are agreeing that you are aware of these limitations.

The materials are provided on an as-is basis without any warranty of any kind, either express or implied. In addition to errors, the information presented may be incomplete or outdated. The information contained is not intended nor recommended as a substitute for professional medical advice. You are advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each device to be used or drug to be administered to verify the dosage, the method and duration of administration, or contraindications. It is the responsibility of the treating physician or other health care professional, relying on independent experience and knowledge of the patient, to determine drug, disease, and the best treatment for the patient.

To the fullest extent permitted by law, HDCN, ASN and their affiliates and suppliers disclaim all warranties, express or implied, including, but not limited to, any warranty of merchantability, non- infringement or fitness for a particular purpose.

In no event shall HDCN, ASN, or their affiliates or suppliers be liable for any damages whatsoever (including, but not limited to, direct, indirect, incidental, consequential, punitive or exemplary damages, or any damages for loss of profits, use, data, goodwill or other intangibles) arising from or in any way relating to these terms, the materials, or any information, goods or services obtained from or referred to in the materials, whether based on warranty, contract, tort (including, but not limited to, negligence), or any other legal theory, and whether or not any or all of the limited entities is advised of the possibility of such damages.